We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-3.61%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$6.41B
AUM Growth
-$663M
Cap. Flow
-$121M
Cap. Flow %
-1.89%
Top 10 Hldgs %
73.95%
Holding
40
New
1
Increased
13
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$260M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$66.3M
3
KYMR icon
Kymera Therapeutics
KYMR
+$47.8M
4
MRUS
Merus
MRUS
+$38.2M
5
ETNB
89bio
ETNB
+$19.7M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$302M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$96.1M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$30.1M
4
UTHR icon
United Therapeutics
UTHR
+$29.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$25.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$26.1B
$825M 12.87%
2,675,000
-85,300
-3% -$29.2M
ASND icon
2
Ascendis Pharma A/S
ASND
$16.5B
$813M 12.69%
5,218,000
+114,945
+2% +$16.4M
ARGX icon
3
argenx
ARGX
$55.2B
$731M 11.41%
1,235,177
-3,290
-0.3% -$2.08M
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.6B
$670M 10.46%
2,022,222
-6,778
-0.3% -$2.23M
KRYS icon
5
Krystal Biotech
KRYS
$10.7B
$492M 7.69%
2,731,000
+102,178
+4% +$17.2M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$341M 5.32%
3,850,000
+2,665,000
+225% +$260M
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
$267M 4.17%
12,222,222
– –
RNAM
8
DELISTED
Avidity Biosciences
RNAM
$225M 3.51%
7,625,000
+125,000
+2% +$3.89M
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.1B
$193M 3.01%
5,741,666
+75,000
+1% +$2.85M
SLNO
10
DELISTED
Soleno Therapeutics
SLNO
$180M 2.82%
2,525,000
– –
KYMR icon
11
Kymera Therapeutics
KYMR
$8.66B
$177M 2.76%
6,460,000
+1,310,000
+25% +$47.8M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.64B
$171M 2.66%
2,674,835
+119,280
+5% +$12.6M
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$167M 2.61%
20,500,000
-2,675,000
-12% -$24.8M
ARWR icon
14
Arrowhead Research
ARWR
$12.1B
$142M 2.21%
11,111,111
– –
VERA icon
15
Vera Therapeutics
VERA
$2.33B
$137M 2.14%
5,701,900
+91,900
+2% +$2.95M
MRUS
16
DELISTED
Merus
MRUS
$126M 1.97%
3,000,000
+875,000
+41% +$38.2M
MLTX icon
17
MoonLake Immunotherapeutics
MLTX
$1.56B
$108M 1.69%
2,770,100
– –
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$82.5M 1.29%
625,000
-2,425,000
-80% -$302M
ALKS icon
19
Alkermes
ALKS
$8.11B
$80.9M 1.26%
2,450,000
– –
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.42B
$65.3M 1.02%
8,700,000
-3,165,000
-27% -$25.5M
OCUL icon
21
Ocular Therapeutix
OCUL
$1.83B
$59.1M 0.92%
8,060,000
– –
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
$58.2M 0.91%
+4,050,000
New +$66.3M
ETNB
23
DELISTED
89bio
ETNB
$46.2M 0.72%
6,350,000
+2,250,000
+55% +$19.7M
MNKD icon
24
MannKind Corp
MNKD
$1.19B
$44M 0.69%
8,750,000
– –
PCVX icon
25
Vaxcyte
PCVX
$7.65B
$37.8M 0.59%
1,000,000
-175,000
-15% -$14M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Avoro Capital Advisors held 40 positions worth $6.41B, down 9.4% from $7.07B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Avoro Capital Advisors's Q1 2025 filing shows 1 new, 13 increased, 7 reduced and 7 closed positions. Its largest new stake was Centessa Pharmaceuticals: 4,050,000 shares worth $58.2M. The largest sale was Intra-Cellular Therapies Inc., an estimated $302M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Avoro Capital Advisors's largest Q1 2025 buy was Centessa Pharmaceuticals: 4,050,000 shares worth $58.2M.
  • Avoro Capital Advisors added most to Blueprint Medicines in Q1 2025, an estimated $260M increase.
  • Avoro Capital Advisors's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $302M.
  • Avoro Capital Advisors fully exited BioMarin Pharmaceuticals in Q1 2025, selling an estimated $96.1M.
  • Avoro Capital Advisors's ten largest holdings make up 74% of its $6.41B portfolio in Q1 2025.
  • Avoro Capital Advisors opened 1 new position and closed 7 in Q1 2025.
  • Avoro Capital Advisors's portfolio value fell 9.4% quarter-over-quarter to $6.41B.

Based on Avoro Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.